Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-22T16:36:52.731Z Has data issue: false hasContentIssue false
  • English
  • Français

Antimicrobial resistance patterns and genotypes of Salmonella enterica serovar Hadar strains associated with human infections in Switzerland, 2005–2010

Published online by Cambridge University Press:  16 April 2013

N. CERNELA ,
M. NÜESCH-INDERBINEN ,
H. HÄCHLER  and
R. STEPHAN
N. CERNELA
Affiliation:
Institute for Food Safety and Hygiene, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
M. NÜESCH-INDERBINEN
Affiliation:
Institute for Food Safety and Hygiene, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
H. HÄCHLER
Affiliation:
Institute for Food Safety and Hygiene, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
R. STEPHAN*
Affiliation:
Institute for Food Safety and Hygiene, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
*
*Author for correspondence: Professor R. Stephan, Institute for Food Safety and Hygiene, Vetsuisse Faculty University of Zurich, Winterthurerstr. 272, CH-8057 Zurich, Switzerland. (Email: [email protected])
Rights & Permissions [Opens in a new window]

Summary

Salmonella Hadar ranks in the top ten serovars reported from humans in Switzerland. In this study, all 64 S. Hadar strains isolated from different patients from 2005 to 2010 in Switzerland were characterized by (i) assessing phenotypic antimicrobial resistance profiles using the disk diffusion method and (ii) by genotyping using pulsed-field gel electrophoresis (PFGE) in order to evaluate the relationship of the strains. The annual incidences varied between 0·32/100 000 in 2005 (highest incidence) and 0·065/100 000 in 2007 (lowest incidence). In total 71·8% of the isolates were resistant to nalidixic acid. Although 40·6% of the strains were resistant to the β-lactam antibiotic ampicillin, they remained susceptible to the third-generation cephalosporin cefotaxime. Genotyping revealed a primary cluster consisting of 42 strains, sharing a similarity of >92%, with a subcluster of 18 strains with indistinguishable patterns. Resistance profiles allowed further differentiation within this subcluster providing a link of two strains to an outbreak in Spain.

Keywords

genotypeshuman infectionsresistance profilesSalmonella Hadar
Type
Original Papers
Information
Epidemiology & Infection , Volume 142 , Issue 1 , January 2014 , pp. 84 - 89
Copyright
Copyright © Cambridge University Press 2013 

INTRODUCTION

Non-typhoidal Salmonella are commonly acquired from contaminated food and are an important cause of gastroenteritis and bacteraemia, posing a worldwide threat to public health [Reference Rabsch, Tschape and Baumler1, Reference Olsen2]. It is estimated that Salmonella causes 93·8 million human infections and 155 000 deaths annually worldwide [Reference Majowicz3]. Although more than 2500 serovars have been identified, S. Enteritidis and S. Typhimurium are responsible for the majority of reported cases of salmonellosis. For Europe, the distribution of other Salmonella serovars is reported to vary widely geographically and over time [Reference Huehn4].

S. Hadar ranks in the top ten serovars isolated from humans in Switzerland over recent years and has been reported to be associated with poultry [5]. This serovar has been responsible for several foodborne outbreaks, e.g. in Italy in 1994 [Reference Fantasia6] and 2000 [Reference Di Giannatale7], and in Spain in 2005 [Reference Lenglet8].

As with other non-typhoidal Salmonella, infections due to S. Hadar often manifest themselves as self-limiting gastroenteritis, but severe invasive infections can also occur which require antimicrobial treatment. Drugs for Salmonella infection include fluoroquinolones, trimethoprim-sulfamethoxazole, ampicillin, or third-generation cephalosporins [Reference Hohmann9]. The emergence and spread of resistant bacteria and subsequent failure of treatment of infections is a significant and increasing global public health problem [10]. Resistance to antimicrobials used to treat invasive Salmonella is also increasing, including extended spectrum cephalosporins and quinolones [Reference Parry11]. S. Hadar is reported less frequently compared to other serovars; nonetheless, these isolates have been described as a reservoir of antimicrobial resistance [Reference Bagger-Skjøt12].

In this study, all 64 S. Hadar strains isolated from different patients from 2005 to 2010 in Switzerland were further characterized by (i) assessing phenotypic antimicrobial resistance profiles using the disk diffusion method and (ii) by genotyping using pulsed-field gel electrophoresis (PFGE) after macrorestriction with XbaI in order to evaluate the relationship of the strains.

METHODS

Strains

Human salmonellosis is a notifiable disease in Switzerland and isolates have to be submitted to the National Centre for Enteropathogenic Bacteria (NENT). NENT, in cooperation with the Swiss Federal Office of Public Health, collects clinical data and conducts final serological identification by slide agglutination with commercial antisera according to the Kauffmann–White scheme [Reference Grimont and Weill13]. From 2005 to 2010, 10 048 cases of Salmonella infection were reported to the Swiss Federal Office of Public Health [14]. During this period, 64 human isolates of S. Hadar were collected and selected for this study. Multiple isolates from the same patient were excluded, isolates from individual family members were regarded as distinct isolates. All samples were collected and submitted by diagnostic laboratories, hospitals or family doctors throughout Switzerland.

Antimicrobial susceptibility testing

The strains were tested for antimicrobial resistance by the disk diffusion method according to the Clinical and Laboratory Standards Institute [15]. The panel of antibiotic disks (Becton, Dickinson and Company, USA) consisted of ampicillin (AM10), amoxicillin/clavulanic acid (AMC30), cephalothin (CF30), cefotaxime (CTX30), ciprofloxacin (CIP5), gentamycin (GM10), tetracycline (Te30), streptomycin (S10), chloramphenicol (C30), kanamycin (K30), nalidixic acid (NA30), sulfamethoxazole (SMZ), and trimethoprim (TMP5). The strains were classified as resistant, intermediate or susceptible to each antimicrobial agent according to CLSI criteria [15]. For calculations of percentages, intermediate susceptibility was considered as resistant. Strains displaying resistance to three or more antimicrobial compounds of different classes were defined as multidrug resistant.

Genotyping

PFGE was performed by following the CDC PulseNet protocol (http://www.cdc.gov/pulsenet/protocols.htm) with minor modifications. In brief, strains were grown on blood agar at 37°C overnight. Colonies from blood agar were re-suspended in cell suspension buffer (OD600 = 1). The bacterial cell suspension was mixed with 400 μl of 1·4% pulsed-field certified agarose (Bio-Rad, Germany) and cells were lysed by proteinase K treatment (0·1 mg/ml at 55°C) overnight. After lysis the plugs were washed twice for 30 min in ultrapure water and four times for 1 h in 0·5 × Tris-EDTA (TE) buffer. After washing with TE buffer, DNA agarose plugs were incubated overnight in the presence of XbaI (Roche, Germany) according to the manufacturer's instructions. Restricted DNA in plug slices was separated in a 1% SeaKem Gold (BioConcept, Switzerland) agarose gel at 6 V/cm in 0·5 × Tris-borate-EDTA buffer cooled to 12°C in a CHEF-DR III system (Bio-Rad). The pulse times were ramped from 2 s to 64 s for 20 h at an angle of 120°. Gels were stained with ethidium bromide and visualized under UV light transillumination with Gel Doc (Bio-Rad) and analysed with BioNumerics software (Applied Maths, Belgium). Pairwise similarities between the XbaI pulsed-field patterns were calculated using the DICE similarity coefficient. Clustering was based on the unweighted pair-group method with averages (UPGMA), setting tolerance and optimization each at 1·5%. S. Braenderup strain H9812 (ATCC BAA 664) was used as a reference strain.

RESULTS

Clinical and epidemiological data

Sixty-one (95%) S. Hadar strains were isolated from stool samples. Of the remaining strains, one originated from a blood sample, one from urine and one isolate was of unknown origin.

During the whole study period S. Hadar was ranked in the top ten serovars reported from humans in Switzerland. Of the total annual Salmonella isolates, this serovar accounted for 1·3% in 2005, 0·6% in 2006, 0·3% in 2007, 0·4% in 2008, 0·8% in 2009 and 0·5% in 2010. The annual incidence of S. Hadar was highest in 2005 with a value of 0·32/100 000. In 2006 the annual incidence was 0·13/100 000, followed by the lowest incidence of 0·065/100 000 in 2007, 0·1/100 000 in 2008, 0·14/100 000 in 2009 and finally, 0·076/100 000 in 2010.

Age was known for 62 of the 64 patients (Fig. 1). In the ⩽5 years age group, eight strains were identified accounting for 12·5% of the study collection. In the 6–14 years age group, four (6·3%) strains were found. The majority of 47 (73·4%) cases was found in the 15–65 years age group; 7·8% of the strains originated from people aged >65 years (five strains).

Fig. 1. Resistance profiles and anamnestic data of the 64 S. Hadar strains. Strains resistant, intermediate or susceptible to a specific antibiotic are highlighted in grey, light grey, or white, respectively. AM, ampicillin; AMC, amoxicillin-clavulanic acid; CF, cephalothin; CTX, cefotaxime; GM, gentamicin; K, kanamycin; S, streptomycin; TE, tetracycline; CIP, ciprofloxacin; NA, nalidixic acid; SMZ, sulfamethoxazole; TMP, trimethoprim; C, chloramphenicol; m, male; f, female; nd, no data.

Of all patients, only three had a documented history of foreign travel. One patient aged >65 years had visited Kenya. Two patients were infants in the <5 years age group; one had been to Macedonia and the other to Egypt. Two patients were members of the same family and both were in the 15–65 years age group.

Antimicrobial susceptibility

A total of 28 (43·8%) strains were resistant and 30 (46·9%) strains revealed multidrug resistance (Fig. 1). Only six (9·4%) strains showed full susceptibility to all antimicrobials.

Resistance rates were high for the quinolone nalidixic acid (71·8%). Only two strains were resistant to ciprofloxacin. The frequency for resistance to tetracycline was 70·3%. For the class of aminogylcosides, resistance to streptomycin was detected in 75% of the strains. All strains were fully susceptible to gentamycin and three (4·7%) strains were resistant to kanamycin.

A high percentage (40·6%) of the strains were resistant to the β-lactam antibiotic ampicillin and 29·7% revealed resistance to the first-generation cephalosporin cephalothin. Four isolates were resistant (intermediate) to the combination of amoxicillin with the β-lactamase inhibitor clavulanic acid and all strains were fully susceptible to the third-generation cephalosporin cefotaxime. Combined resistance to ampicillin and nalidixic acid was exhibited by 24 strains (37·5%). We found 21 sulfamethoxazole- and three trimethoprim-resistant strains, which amounted to 32·8% and 4·7%, respectively. Three strains were resistant to both antimicrobials. All isolates except two (3·1%) were susceptible to chloramphenicol.

From 2005 to 2010 no major shift in resistance patterns was observed. However, resistance rates were maintained at high levels. In different years 80–100% of the isolated strains were resistant to at least one antimicrobial.

Genetic relationship of Swiss S. Hadar isolates

PFGE analysis with the XbaI restriction enzyme revealed 34 banding patterns in the 64 isolates (Fig. 2). In general, PFGE analysis of the different strains showed a close clonal relationship. One primary cluster was observed, consisting of 42 strains sharing a similarity of >92%. Within this cluster 18 strains shared a similarity of 100%. Eight of these indistinguishable strains were isolated in 2005, which amounted to 33·3% of the 24 isolates collected in 2005. In the following years, this pulsotype appeared less frequently (in 2006 two strains were detected, in 2007 there was one strain, in 2008 we found three, in 2009 there were four, and in 2010 one strain was found). Except for strains N05-1373 and N05-1374, which originated from two individuals from the same family, no connection between the patients could be established. Samples had been obtained and submitted to NENT from all over Switzerland. Age groups and gender were distributed evenly and all strains originated from stool samples.

Fig. 2. Pulsed-field gel electrophoresis (PFGE) patterns of the 64 S. Hadar strains. The primary PFGE cluster (92% similarity) is indicated by light grey.

Two of these 18 strains (N05-1374, N06-1737) showed the resistance pattern AM-CF-S-NA-TE; four strains (N05-216, N05-1556, N05-1957, N09-1491) showed the resistance pattern AM-CF-S-NA-TE-SMZ and the rest of these 18 strains were heterogeneous in regard to their resistances.

DISCUSSION

On average, the annual incidence of salmonellosis in Switzerland for 2005–2010 was 21·78/100 000 [14]. From this period, isolates from 64 cases of human infections with S. Hadar were selected and screened for antibiotic resistance and for genetic relationship. Strains were from medical institutions from all over Switzerland.

In an analysis of the global distribution of the 15 most frequently identified serovars of Salmonella isolated from humans, S. Hadar was found in a proportion of 1·5% in Europe [Reference Hendriksen16]. In Switzerland, S. Hadar ranked in the top ten serovars reported from humans during to whole study period.

Although salmonellosis is a notifiable disease, it is normally self-limiting in otherwise healthy individuals and hence many infections go undetected by the authorities, accounting for an unknown number of unreported cases. It has been suggested that reported laboratory-confirmed Salmonella incidences should be adjusted for under-ascertainment using multipliers ranging from 3·2 to 14·3 for European countries and as high as 38 for the USA [Reference Majowicz3]. Consequently, it must be assumed that the true population burden of disease caused by S. Hadar is greater than that suggested by our findings.

We found that the majority of strains were resistant to nalidixic acid, tetracycline and β-lactam antibiotics, excluding third-generation cephalosporins. The emergence and spread of multidrug resistance in pathogenic as well as commensal bacteria in general and in Salmonella spp. in particular is an increasing global concern [10, Reference van den Bogaard and Stobberingh17, Reference Threlfall18]. Dissemination of resistance genes through bacterial populations needs to be monitored globally as well as locally [Reference O'Brien19]. Moreover, there is evidence that less frequent serovars, such as S. Hadar, are reservoirs of antibiotic resistance genes [Reference Bagger-Skjøt12]. The considerable percentage (46·9%) of multidrug-resistant strains in our strain collection is in accord with the results of a European multi-centre study, which describes 37% multidrug-resistant Salmonella isolates [Reference Threlfall20].

Reisistance to nalidixic acid in salmonellae is of great concern, as it has been reported to be an indicator for reduced susceptibility to the drug of choice, ciprofloxacin, resulting in possible treatment failure [Reference Hakanen21–Reference Crump23]. Consequently, the 71·8% nalidixic acid-resistant S. Hadar of this study must be considered as having reduced susceptibility to ciprofloxacin, and thus potentially treatment-resistant. Interestingly, the strain that was isolated from blood, and presumably associated with invasive infection, was susceptible to both nalidixic acid and ciprofloxacin.

Reports on the emergence of extended-spectrum β-lactamase (ESBL)-resistant salmonellae give rise to concern [Reference Coque, Baquero and Canton24]. Genes encoding for ESBLs, predominantly bla TEM, bla SHV and bla CTX variants have been detected in various Salmonella serovars isolated from humans as well as from poultry and poultry products [Reference Hasman25]. However, all the S. Hadar isolates in this study were susceptible to cefotaxime. So far, resistance to ESBL antibiotics is not yet an issue in S. Hadar isolates in Switzerland. Nevertheless, continued surveillance for the presence of ESBL in Salmonella spp. is needed in order to minimize the risks to future treatment [Reference Yates and Amyes26].

PFGE analysis showed a close clonal relationship for this serovar, similar to what is also known for S. Enteritidis. In the primary cluster, consisting of 42 strains sharing a similarity of >92%, a subcluster of 18 strains with indistinguishable patterns was observed. By combining the PFGE and the resistance patterns of these strains, two strains (N05-1374, N06-1737) isolated in 2005 and early 2006 are indistinguishable from a S. Hadar strain responsible for a chicken meat-borne outbreak in Spain [Reference Lenglet8], suggesting a possible exposure of these patients in Spain.

ACKNOWLEDGEMENTS

We thank Grethe Sägesser for her help in strain collection and technical support and the Swiss Federal Office of Public Health for financial support. We also thank Silvia Herrera Leon for providing the pattern of the S. Hadar outbreak strain from 2005 in Spain.

DECLARATION OF INTEREST

None.

References

REFERENCES

1. Rabsch, W, Tschape, H, Baumler, AJ. Non-typhoidal salmonellosis: emerging problems. Microbes and Infection 2001; 3: 237–247.Google Scholar
2. Olsen, SJ, et al. The changing epidemiology of salmonella: trends in serovars isolated from humans in the United States, 1987–1997. Journal of Infectious Disease 2001; 183: 753–761.Google Scholar
3. Majowicz, SE, et al. The global burden of nontyphoidal salmonella gastroenteritis. Clinical Infectious Disease 2010; 50: 882–889.Google Scholar
4. Huehn, S, et al. Virulotyping and antimicrobial resistance typing of Salmonella enterica serovars relevant to human health in Europe. Foodborne Pathogen and Diseases 2010; 7: 523–535.Google Scholar
5. Anon. European Food Safety Authority (EFSA) (http://www.efsa.europa.eu/de/scdocs/doc/1533.pdf). Accessed 29 January 2013.Google Scholar
6. Fantasia, M, et al. Conventional and molecular approaches to isolates of Salmonella Hadar from sporadic and epidemic cases. Journal of Applied Microbiology 1997; 82: 494–498.CrossRefGoogle ScholarPubMed
7. Di Giannatale, E, et al. Investigation of an outbreak of Salmonella enterica subsp. enterica serovar Hadar food illness in the Abruzzi region of Italy. Veterinary Italian 2008; 44: 405–427.Google Scholar
8. Lenglet, A. Over 2000 cases so far in Salmonella Hadar outbreak in Spain associated with consumption of pre-cooked chicken, July–August, 2005. Eurosurveillance 2005; 11: 10(8).Google Scholar
9. Hohmann, EL. Nontyphoidal salmonellosis. Clinial Infectious Disease 2001; 32: 263–269.Google Scholar
10. Anon. World Health Organisation: tackling antibiotic resistance from a food safety perspective in Europe. Copenhagen, 2011.Google Scholar
11. Parry, CM. Antimicrobial drug resistance in Salmonella enterica . Current Opinion in Infectious Diseases 2003; 16: 467–472.Google Scholar
12. Bagger-Skjøt, L, et al. Less frequent Salmonella serovars as a reservoir of antimicrobial resistance. Journal of Antimicrobial Chemotherapy 2007; 59: 814–815.Google Scholar
13. Grimont, PAD, Weill, FX. Antigenic Formulae of the Salmonella Serovars, 9th edn. WHO Collaborating Center for Reference and Research on Salmonella, Institut Pasteur: Paris, 2007.Google Scholar
14. Anon. Swiss Federal Office for Public Health (http://www.bag.admin.ch/k_m_meldesystem/00733/00813/). Accessed 29 January 2013.Google Scholar
15. CLSI. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI document M100-S18 2008, Wayne, PA.Google Scholar
16. Hendriksen, RS, et al. Global monitoring of salmonella serovar distribution from the World Health Organization global foodborne infections network country data bank: Results of quality assured laboratories from 2001 to 2007. Foodborne Pathogens and Diseases 2011; 8: 887–900.CrossRefGoogle ScholarPubMed
17. van den Bogaard, AE, Stobberingh, EE. Epidemiology of resistance to antibiotics. Links between animals and humans. International Journal of Antimicrobial Agents 2000; 14: 327–335.Google Scholar
18. Threlfall, EJ, et al. The emergence and spread of antibiotic resistance in food-borne bacteria. International Journal of Food Microbiology 2000; 62: 1–5.Google Scholar
19. O'Brien, TF. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clinical Infectious Diseases 1997; 24: 2–8.Google Scholar
20. Threlfall, EJ, et al. Antimicrobial drug resistance in isolates of Salmonella enterica from cases of salmonellosis in humans in Europe in 2000: results of international multi-centre surveillance. Eurosurveillance 2003; 8: 41–45.Google Scholar
21. Hakanen, A, et al. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. Journal of Clinical Microbiology 1999; 37: 3572–3577.Google Scholar
22. Møller Aarestrup, F, Wiuff, C. Is it time to change fluoroquinolone breakpoints for Salmonella spp? Antimicrobial Agents Chemotherapy 2003; 47: 827–829.Google Scholar
23. Crump, JA, et al. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serovar Typhi and for non-typhi salmonellae. Clinical Infectious Diseases 2003; 37: 75–81.Google Scholar
24. Coque, TM, Baquero, F, Canton, R. (2008) Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance 2008; 20: 13(47).Google Scholar
25. Hasman, H, et al. Beta-lactamases among extended-spectrum beta-lactamase (ESBL)-resistant Salmonella from poultry, poultry products and human patients in The Netherlands. Journal of Antimicrobial Chemotherapy 2005; 56: 115–121.CrossRefGoogle ScholarPubMed
26. Yates, C, Amyes, S. Extended-spectrum beta-lactamases in non-typhoidal Salmonella spp. isolated in the UK are now a reality: why the late arrival? Journal of Antimicrobial Chemotherapy 2005; 56: 262–264.Google Scholar
Figure 0

Fig. 1. Resistance profiles and anamnestic data of the 64 S. Hadar strains. Strains resistant, intermediate or susceptible to a specific antibiotic are highlighted in grey, light grey, or white, respectively. AM, ampicillin; AMC, amoxicillin-clavulanic acid; CF, cephalothin; CTX, cefotaxime; GM, gentamicin; K, kanamycin; S, streptomycin; TE, tetracycline; CIP, ciprofloxacin; NA, nalidixic acid; SMZ, sulfamethoxazole; TMP, trimethoprim; C, chloramphenicol; m, male; f, female; nd, no data.

Figure 1

Fig. 2. Pulsed-field gel electrophoresis (PFGE) patterns of the 64 S. Hadar strains. The primary PFGE cluster (92% similarity) is indicated by light grey.